Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

Main Article Content

James Q Del Rosso
JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV Touro University, Henderson, NV

Corey L Hartman
Skin Wellness Dermatology, Birmingham, AL University of Alabama Birmingham, AL

Caitlin Lewis
Clewy Communications, Raleigh, NC

Rhonda Schreiber
Mayne Pharma, Greenville, NC

Keywords

acne, tazarotene

Abstract

Abstract not available.

References

1. Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M. Global Alliance to Improve Outcomes in Acne Large scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010 Apr;49(4):448-56.

2. Kircik LH. Importance of vehicles in acne therapy. J Drugs Dermatol. 2011 Jun;10(6):s17-23.

3. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles Vehicle Characteristics Can Influence and Improve Patient Outcomes. J Drugs Dermatol. 2019 Feb 1;18(2s):s100-s107.

4. Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 Jul;94(1):46-53.

5. Smith JA, Narahari S 2 Hill D, Feldman SR. Tazarotene foam, 0.1% for the treatment of acne. Expert Opin Drug Saf. 2016 Jan;15(1):99-103.

6. Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1% in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr:12(4):438-46.

7. Epstein EL, Stein Gold L. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2013 May;14(6):123-5.

8. Data on file, Mayne Pharma

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.4

Article Details

How to Cite
Del Rosso, J. Q., Hartman, C. L., Lewis, C., & Schreiber, R. (2019). Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine, 3, S4. https://doi.org/10.25251/skin.3.supp.4
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Acne & Rosacea
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>